KTN's online platform helps you to make the connections you need


The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.


The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

AstraZeneca teams with Venter to mine genomes for R&D insights

The tech mantra of better, faster, cheaper has slashed the cost of genomic sequencing to a tiny fraction of the original expense. And now AstraZeneca says the time is perfect to launch an ambitious partnership with Craig Venter’s Human Longevity to do a mass sequencing project aimed at illuminating a path to new and better drugs.

The pharma giant is creating an in-house Centre for Genomics Research which will gather information from two million genome sequences, a mega database that will incorporate sequencing on 500,000 samples gathered during its clinical trials.

The new project, which follows a variety of similar efforts by biopharma players like Amgen and Regeneron, will be used to ID new drug targets, identify the right patients for its trials and help push along the effort on personalized medicines--matching the right drug with the right patients.

Human Longevity will be doing the sequencing on AstraZeneca’s 500,000 DNA samples, while Venter’s company will open its vaults to AstraZeneca’s global R&D group. Wellcome Trust Sanger Institute, UK, and The Institute for Molecular Medicine, Finland, are also participating.

Read the full article here